keyword
MENU ▼
Read by QxMD icon Read
search

"Hepatitis c" cost

keyword
https://www.readbyqxmd.com/read/29786879/comorbidity-of-viral-hepatitis-and-chronic-spontaneous-urticaria-a-systematic-review
#1
REVIEW
Pavel Kolkhir, Natalia Pereverzina, Olga Olisova, Marcus Maurer
Chronic viral infections including those by hepatitis B (CHB) virus and hepatitis C (CHC) virus have been reported to be comorbidities of chronic spontaneous urticaria (CSU). Here, we performed the first comprehensive review of the peer-reviewed literature (Pubmed, Web of Science and Google Scholar) on the prevalence of CHB and CHC in patients with CSU and vice versa. The prevalence of CHB and CHC in CSU does not appear to be increased. Less than 5% and less than 2% of CSU patients have markers of CHB and CHC, respectively, according to most of the 32 studies reviewed...
May 22, 2018: Allergy
https://www.readbyqxmd.com/read/29778265/a-guide-to-the-economics-of-hepatitis-c-virus-cure-in-2017
#2
REVIEW
Benjamin P Linas, Shayla Nolen
This commentary reviews the core principals of cost-effectiveness and applies them to the rapidly evolving context of hepatitis C virus treatment in the United States. The article provides a foundation of evidence that hepatitis C virus treatment provides good economic value, even though it is expensive, and even when treating people who inject drugs who are at high risk for hepatitis C virus reinfection. The price of medications has decreased, but the high price continues to limit access to care. This wedge between cost effectiveness and affordability stands front and center as one of the leading obstacles to elimination...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29778259/five-questions-concerning-managing-hepatitis-c-in-the-justice-system-finding-practical-solutions-for-hepatitis-c-virus-elimination
#3
REVIEW
Anne C Spaulding, Madeline G Adee, Robert T Lawrence, Jagpreet Chhatwal, William von Oehsen
An estimated 30% of Americans with hepatitis C virus (HCV) pass through a jail or prison annually. One in 7 incarcerated persons is viremic. Screening and treatment is cost-effective and beneficial to society as a whole. Yet at current (2018) levels of funding for HCV management, prisons are not aggressively seeking cases; few incarcerated persons with HCV actually receive treatment. This article explores barriers to screening for and treating hepatitis C in state prisons, and ways that states may overcome these barriers, such as nominal pricing...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29775725/anti-hepatitis-c-virus-activity-and-synergistic-effect-of-nymphaea-alba-extracts-and-bioactive-constituents-in-liver-infected-cells
#4
Sidra Rehman, Usman Ali Ashfaq, Bushra Ijaz, Sheikh Riazuddin
BACKGROUND: Without an effective vaccine, hepatitis C virus (HCV) remains a global threat, inflicting 170-300 million carriers worldwide at risk of cirrhosis and hepatocellular carcinoma (HCC). Though various direct acting antivirals have been redeemed the hepatitis C treatment, a few restraints persist including possible side effects, viral resistance emergence, excessive cost which restricts its availability to a common person. HYPOTHESIS: There is no preventive HCV vaccine available today so the discovery of potent antiviral natural flora and their bioactive constituents may help to develop preventive cures against HCV infection...
May 15, 2018: Microbial Pathogenesis
https://www.readbyqxmd.com/read/29753282/efficient-hptlc-dual-wavelength-spectrodensitometric-method-for-simultaneous-determination-of-sofosbuvir-and-daclatasvir-biological-and-pharmaceutical-analysis
#5
Mohammad Nabil Abo-Zeid, Samia M El-Gizawy, Noha N Atia, Salwa R El-Shaboury
Sofosbuvir (SOF) and daclatasvir (DCS) are newly discovered anti-hepatitis C drugs that have direct antiviral activity. A novel and simple high-performance thin-layer chromatography (HPTLC) method was designed for simultaneous determination of SOF and DCS in miscellaneous matrices. The method adopts coupling HPTLC with dual wavelength spectrodensitometry. Consequently, this enabled sensitive, specific and cost-effective determination of the SOF-DCS mixture. The developed HPTLC procedure is based on a simple liquid-liquid extraction, enrichment of the analytes and subsequent chromatographic separation with UV detection...
May 1, 2018: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/29750893/disparities-in-initiation-of-direct-acting-antiviral-agents-for-hepatitis-c-virus-infection-in-an-insured-population
#6
Julia L Marcus, Leo B Hurley, Scott Chamberland, Jamila H Champsi, Laura C Gittleman, Daniel G Korn, Jennifer B Lai, Jennifer O Lam, Mary Pat Pauly, Charles P Quesenberry, Joanna Ready, Varun Saxena, Suk I Seo, David J Witt, Michael J Silverberg
OBJECTIVES: The cost of direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection may contribute to treatment disparities. However, few data exist on factors associated with DAA initiation. METHODS: We conducted a retrospective cohort study of HCV-infected Kaiser Permanente Northern California members aged ≥18 during October 2014 to December 2016, using Poisson regression models to evaluate demographic, behavioral, and clinical factors associated with DAA initiation...
January 1, 2018: Public Health Reports
https://www.readbyqxmd.com/read/29743153/integrated-models-of-care-for-people-living-with-hepatitis-c-virus-and-a-substance-use-disorder-protocol-for-a-systematic-review
#7
Lianping Ti, Stephanie Parent, María Eugenia Socías
BACKGROUND: People living with a substance use disorder (SUD) are a key population within the hepatitis C virus (HCV) epidemic. While integrated and community-based models of care have shown positive outcomes among this population, the literature has been primarily focused on the HIV context. This paper outlines a systematic review protocol on the impact of various integrated models of care, which includes HCV and SUD services, on various treatment, and health-related outcomes among this population...
May 9, 2018: JMIR Research Protocols
https://www.readbyqxmd.com/read/29739068/performance-evaluation-of-protein-chip-assay-for-rapid-diagnosis-of-hepatitis-c-virus-infection-in-injection-drug-abusers
#8
Zhiyan Dai, Xin Shu, Gang Li, Weidong Xi
BACKGROUND: We evaluated the performance of a protein chip assay for the detection of antibodies to hepatitis C virus (HCV) peptides among injection drug abusers (IDAs) by comparing the assay with existing methods, including enzyme-linked immunosorbent assay (ELISA), reverse transcription-polymerase chain reaction (RT-PCR), and recombinant immunoblot assay (RIBA). METHODS: Seventy serum samples collected from IDAs were analyzed by protein chip assay. ELISA, RT-PCR, and RIBA assay were used to validate the results...
April 1, 2018: Clinical Laboratory
https://www.readbyqxmd.com/read/29737209/inhibitory-effects-of-amentoflavone-and-orobol-on-daclatasvir-induced-resistance-associated-variants-of-hepatitis-c-virus
#9
Wei-Ping Lee, Keng-Li Lan, Shi-Xian Liao, Yi-Hsiang Huang, Ming-Chih Hou, Keng-Hsin Lan
Hepatitis C virus (HCV) is recognized as a major causative agent of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Despite rapid progress in the development of direct-acting antivirals (DAA) against HCV infection in recent years, cost-effective antiviral drugs with more affordable prices still need to be developed. In this study, we screened a library of natural compounds to identify natural HCV inhibitors. The library of the pure compounds extracted from Chinese herbs deposited in the chemical bank of National Research Institute of Chinese Medicine (NRICM), Taiwan was screened in the cell culture-derived HCV (HCVcc) system...
May 8, 2018: American Journal of Chinese Medicine
https://www.readbyqxmd.com/read/29734473/treatment-for-hepatitis-c-virus-associated-mixed-cryoglobulinaemia
#10
REVIEW
Nuria Montero, Alexandre Favà, Eva Rodriguez, Clara Barrios, Josep M Cruzado, Julio Pascual, Maria Jose Soler
BACKGROUND: Hepatitis C virus (HCV)-associated mixed cryoglobulinaemia is the manifestation of an inflammation of small and medium-sized vessels produced by a pathogenic IgM with rheumatoid factor activity generated by an expansion of B-cells. The immune complexes formed precipitate mainly in the skin, joints, kidneys or peripheral nerve fibres. Current therapeutic approaches are aimed at elimination of HCV infection, removal of cryoglobulins and also of the B-cell clonal expansions. The optimal treatment for it has not been established...
May 7, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29716179/recent-update-of-the-2017-korean-association-for-the-study-of-the-liver-kasl-treatment-guidelines-of-chronic-hepatitis-c-comparison-of-guidelines-from-other-continents-2017-aasld-idsa-and-2016-easl
#11
Jong Eun Yeon
The paradigm for the treatment of chronic hepatitis C (CHC) has been changed due to the development of direct acting antivirals (DAAs) of hepatitis C virus (HCV). The high sustained virologic response rate and ease of administration makes the DAAs approach ideal to contribute to the complete eradication of HCV. Currently, treatment options for individual patients vary depending on the genotype or subtype of HCV, presence or absence of liver cirrhosis, previous experience of antiviral treatment or resistance associated substitutions...
May 2, 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29701909/the-impact-of-direct-acting-antiviral-agents-on-liver-and-kidney-transplant-costs-and-outcomes
#12
D A Axelrod, M A Schnitzler, T Alhamad, F Gordon, R D Bloom, G P Hess, H Xiao, M Nazzal, D L Segev, V R Dharnidharka, A S Naik, N N Lam, R Ouseph, B L Kasiske, C Durand, K L Lentine
Direct-acting antiviral medications (DAAs) have revolutionized care for hepatitis C positive (HCV+) liver (LT) and kidney (KT) transplant recipients. SRTR registry data were integrated with national pharmaceutical claims (2007-2016) to identify HCV treatments before 1/2014 (pre-DAA) and after (post-DAA), stratified by donor (D) and recipient (R) serostatus and payer. Pre-DAA, 18% of HCV+ LT recipients were treated within 3 years and without differences by donor serostatus or payer. Post-DAA, only 6% of D-/R+ recipients, 19...
April 27, 2018: American Journal of Transplantation
https://www.readbyqxmd.com/read/29696459/economic-evaluation-of-zepatier-for-the-management-of-hcv-in-the-italian-scenario
#13
F R Rolli, M Ruggeri, F Kheiraoui, C Drago, M Basile, C Favaretti, A Cicchetti
BACKGROUND: Hepatitis C virus (HCV) is a major health issue worldwide. New generation of direct-active antiviral medications is an epoch-making turning point in the management of HCV infections. OBJECTIVE: Conducing a cost-effectiveness analysis comparing the combination of elbasvir/grazoprevir and sofosbuvir + pegylated interferon/ribavirin for the management of all HCV patients (even those in the initial stages of fibrosis). METHODS: A Markov model was built on the natural history of the disease to assess the efficacy of the alternatives...
April 25, 2018: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/29692878/newly-diagnosed-hepatitis-c-in-the-us-commercially-insured-population-before-and-after-the-2012-implementation-of-expanded-screening-guidelines
#14
Bruce S Pyenson, Gabriela Dieguez, Christine Ferro, Maushumi Mavinkurve, Yuri Sanchez Gonzalez
Background: In the United States in 2014, more than 3 million individuals were estimated to have chronic hepatitis C virus (HCV) infection, including many undiagnosed individuals. In 2012, the Centers for Disease Control and Prevention expanded its HCV testing recommendations to target all adults born between 1945 and 1965, in addition to at-risk individuals, which has led to an increase in newly diagnosed patients. Few studies have explored the medical cost or clinical status of patients who are newly diagnosed with HCV...
February 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29689073/liver-disease-burden-and-required-treatment-expenditures-for-hepatitis-c-virus-hcv-infection-in-thailand-implications-for-hcv-elimination-in-the-new-therapeutic-era-a-population-based-study
#15
Rujipat Wasitthankasem, Preeyaporn Vichaiwattana, Nipaporn Siripon, Nawarat Posuwan, Chompoonut Auphimai, Sirapa Klinfueng, Napha Thanetkongtong, Viboonsak Vuthitanachot, Supapith Saiyatha, Chaiwat Thongmai, Saowakon Sochoo, Natnada Pongsuwan, Kittiyod Poovorawan, Pisit Tangkijvanich, Yong Poovorawan
The prevalence of hepatitis C virus (HCV) infection has been decreasing globally, but the growing effects of HCV-related morbidity and mortality remain of concern. Advances in curative medicine, involving direct-acting antivirals (DAAs), have led many countries to aim to eradicate HCV. Information on epidemiology and disease burden is essential for national policy development. Thus, this study aimed to determine the HCV-related hepatic disease burden in areas of Thailand with high and average HCV prevalence in order to extrapolate the viral burden across Thailand...
2018: PloS One
https://www.readbyqxmd.com/read/29687790/-direct-hospitalization-costs-associated-with-chronic-hepatitis-c-in-the-valencian-community-in-2013
#16
Isabel Barrachina Martínez, Remedios Giner Durán, David Vivas-Consuelo, Antonio López Rodado, José Alberto Maldonado Segura
OBJECTIVE: Hospital costs associated with Chronic Hepatitis C (HCC) arise in the final stages of the disease. Its quantification is very helpful in order to estimate and check the burden of the disease and to make financial decisions for new antivirals. The highest costs are due to the decompensation of cirrosis. METHODS: Cross-sectional observational study of hospital costs of HCC diagnoses in the Valencian Community in 2013 (n= 4,486 hospital discharges). Information source: Minimum basic set of data/ Basic Minimum Data Set...
April 23, 2018: Revista Española de Salud Pública
https://www.readbyqxmd.com/read/29682307/bioequivalent-pharmacokinetics-for-generic-and-originator-hepatitis-c-direct-acting-antivirals
#17
EDITORIAL
Andrew Hill, Loai Tahat, Mohammed Khalil Mohammed, Rabab Fayez Tayyem, Giten Khwairakpam, Sanjay Nath, James Freeman, Ismahane Benbitour, Sherine Helmy
Mass production of low-cost, generic direct-acting antivirals (DAAs) will be required to achieve targets of eliminating hepatitis C (HCV) by 2030. The pharmaceutical companies Gilead and Bristol-Myers Squibb have granted voluntary licences (VLs) to generic companies to mass produce the DAAs sofosbuvir and daclatasvir at low cost. However, generic manufacturers need to demonstrate bioequivalent pharmacokinetics for their DAAs, compared to the originator versions, to fulfil World Health Organization standards for prequalification...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29679811/hepatitis-c-care-continuum-and-associated-barriers-among-people-who-inject-drugs-in-chennai-india
#18
Eshan U Patel, Sunil S Solomon, Allison M Mcfall, Aylur K Srikrishnan, Amrose Pradeep, Paneerselvam Nandagopal, Oliver Laeyendecker, Aaron A R Tobian, David L Thomas, Mark S Sulkowski, M Suresh Kumar, Shruti H Mehta
BACKGROUND: Little is known regarding barriers to hepatitis C virus (HCV) treatment among people who inject drugs (PWID) in low-resource settings, particularly in the era of direct-acting antiviral therapies. METHODS: Between March, 2015-August, 2016, a cross-sectional survey was administered to community-based PWID in Chennai, India to examine the HCV care continuum and associated barriers. Adjusted prevalence ratios (APR) were estimated by multivariable Poisson regression with robust variance...
April 18, 2018: International Journal on Drug Policy
https://www.readbyqxmd.com/read/29675692/uptake-of-and-expenditure-on-direct-acting-antiviral-agents-for-hepatitis-c-treatment-in-australia
#19
Barbara de Graaff, Kwang Chien Yee, Philip Clarke, Andrew Palmer
BACKGROUND: Direct-acting antiviral agents (DAAs) have revolutionised treatment for the hepatitis C virus (HCV). Currently, treatment costs between 20,000 and 80,000 Australian dollars ($A) per patient. The Australian Federal Government provided $A1 billion over 5 years to subsidise these drugs. OBJECTIVE: The aim of this paper was to evaluate the uptake and financial impact of DAA prescribing in Australia. METHODS: We undertook a retrospective analysis of Medicare prescription and expenditure data for March 2016 to August 2017...
April 19, 2018: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/29671198/cancer-community-education-in-somali-refugees-in-nebraska
#20
Shinobu Watanabe-Galloway, Nada Alnaji, Brandon Grimm, Melissa Leypoldt
Nebraska has one of the highest numbers of refugees per capita in the U.S. A high number of Somalis have resettled in Nebraska due to job opportunities and the low cost of living. In this paper, we report the process and the results of a cervical and breast cancer education program for Somali women conducted through a collaboration among public health, academia, and community entities. The curriculum was built to be suitable for the literacy level and cultural values of this community. Topics include female reproductive anatomy; breast and cervical cancer knowledge and screening; hepatitis C and liver cancer; and preparing for a health screening visit...
April 18, 2018: Journal of Community Health
keyword
keyword
90225
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"